Showing results (71-80 of 258) with videos related to
Sort By:
Pageof 26
Biochimica Et Biophysica Acta|January 24, 2007
Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcuminYunjin Jung, Wanping Xu, Heejung Kim, et al.Scientific Reports|December 6, 2019
Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-MycCarole Sourbier, Christopher J Ricketts, Pei-Jyun Liao, et al.Oncotarget|May 18, 2011
Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivityMehdi Mollapour, Shinji Tsutsumi, Yeong Sang Kim, et al.Cell Stress & Chaperones|January 16, 2019
The IXth CSSI international symposium on heat shock proteins in biology and medicine: stress responses in health and disease : Alexandria Old Town, Alexandria, Virginia, November 10-13, 2018Stuart K Calderwood, Elizabeth A Repasky, Len Neckers, et al.Molecular Cancer Research : MCR|September 13, 2006
Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcadeEdward G Mimnaugh, Wanping Xu, Michele Vos, et al.Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancerYisong Wang, Jane B Trepel, Leonard M Neckers, et al.Cell Cycle (Georgetown, Tex.)|September 1, 2012
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cellsAki Iwai, Dimitra Bourboulia, Mehdi Mollapour, et al.The Journal of Biological Chemistry|December 19, 2002
Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha proteinYun-Jin Jung, Jennifer S Isaacs, Sunmin Lee, et al.Proceedings of the National Academy of Sciences of the United States of America|September 20, 2002
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/NeuWanping Xu, Monica Marcu, Xitong Yuan, et al.Molecular Cancer Therapeutics|February 18, 2003
17AAG: low target binding affinity and potent cell activity--finding an explanationGabriela Chiosis, Henri Huezo, Neal Rosen, et al.Pageof 26